Corifarma ehf. and Midas Pharma GmbH entered into an exclusive out-licensing cooperation for the European territory (incl. Turkey and Russia). The respective product can be launched in the EU in 2023 as a generic and is used in treatment of HIV/AIDS.
Combining the extensive market knowledge of Midas and Coripharma’s long-established expertise in pharmaceutical finished dosage form development and manufacturing, the parties are able to offer their marketing partners a generic dossier (film-coated tablets, 400 and 600 mg) for in-licensing.
Coripharma is an European generic pharmaceutical company, based on solid heritage. Their manufacturing site was initially established in 1981, for local pharmaceutical production in Iceland.
With regular launches on day one, often as the first generic pharmaceutical company to market after patents expired in Europe, the manufacturing site played an important role in the growth story of Actavis. The business expanded from a local manufacturer in Iceland to one of the biggest generic players in Europe and in the world. Coripharma acquired the former Actavis manufacturing and R&D site in 2018/2019.
Coripharma specializes in pharmaceutical contract manufacturing solid oral dosage forms, conventional and controlled pharmaceutical products, with annual production capacity of 1.2 billion units.